Andrew K. Balo

Board Member

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

Affiliation history

Recorded current and former roles; source labels appear when available.

Recorded roles and earnings-call appearances connecting this person to public companies.

DXCM

Current role

GCTK

Current role

Board Member

2024-01-01–present

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year	Company	Role	Salary	Bonus	Stock awards	Option awards	Incentive	Other	Total
2019	Dexcom Inc (DXCM)	EVP, Regulatory Strategy, Clinical Affairs, and Strategic Partnership Development	$384,300	$7,500	$2,146,723	—	$461,160	$23,007	$3,022,690
2018	Dexcom Inc (DXCM)	EVP, Regulatory Strategy, Clinical Affairs, and Strategic Partnership Development	$365,959	$7,500	$2,317,820	—	$461,108	$22,251	$3,174,638
2017	Dexcom Inc (DXCM)	EVP, Regulatory Strategy, Clinical Affairs, and Strategic Partnership Development	$355,300	—	$2,250,232	—	$389,054	$22,325	$3,016,911

No earnings-call appearances or filed executive changes recorded yet.